besthealtharticle.com
Home »
NEW YORK (Reuters Health) – Pooled clinical-trial data show that teprotumumab improves eye bulging and double vision in patients with active thyroid eye disease, with most patients having long-lasting responses. The data clearly show that teprotumumab “mitigates varying levels of disease severity, including proptosis and diplopia, which are the most progressive and difficult findings to […]
NEW YORK (Reuters Health) – In patients with non-small cell lung cancer brain metastases (NSCLCBM) treated with immune-checkpoint inhibitors (ICIs) and upfront steroids, a low neutrophil-to-lymphocyte ratio (NLR) was associated with lower overall survival in a single-center retrospective analysis. “With widespread implementation of ICIs for treatment of NSCLC, many clinicians have concerns that the immunosuppressive […]
The combination of copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death, when compared with rituximab plus placebo in a phase 3 trial of patients with relapsed, indolent non-Hodgkin lymphoma (NHL). The trial, dubbed CHRONOS-3, is the first to report “a broad benefit” across histologic subtypes of relapsed, indolent […]
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. An independent data monitoring committee is recommending stopping enrollment of a phase 3 trial of a monoclonal antibody for COVID-19 because interim results indicate an 85% (P = .002) reduction in hospitalizations or death, two companies have announced. Vir Biotechnology and […]
ZURICH (Reuters) – Vaccines from AstraZeneca, Russia’s Gamaleya Institute and Johnson & Johnson fight the coronavirus with another virus, leaving scientists concerned the shots may lose potency if annual inoculations become necessary to fight new variants. So-called viral vector shots – also used by several Chinese COVID-19 vaccine developers – use harmless modified viruses as […]